Literature DB >> 3819940

New England Maternal PKU Project: prospective study of untreated and treated pregnancies and their outcomes.

F J Rohr, L B Doherty, S E Waisbren, I V Bailey, M G Ampola, B Benacerraf, H L Levy.   

Abstract

Four women with classic phenylketonuria (blood phenylalanine greater than 1200 mumol/L) were given a phenylalanine-restricted diet; three also received L-tyrosine supplements. Biochemical measures of nutrition were normal except for iron deficiency anemia, and in one woman folate deficiency. One pregnancy in which treatment began before conception and another treated from 8 weeks gestation, both with blood phenylalanine levels maintained at 120 to 730 mumol/L, resulted in normal newborn infants whose postnatal growth and development have also been normal. A third pregnancy, treated from 6 gestational weeks, was marked by poor dietary compliance until the middle of the second trimester; fetal microcephaly was identified by ultrasonography at 28 weeks but not at 21 weeks. The child has microcephaly and motor delay. The fourth pregnancy, not treated until the third trimester, produced a child with microcephaly, mental retardation, hyperactivity, and neurologic deficits. It is likely that fetal damage from maternal phenylketonuria can be largely and perhaps entirely prevented by dietary therapy, but therapy must begin before conception for the best chance of a normal infant.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3819940     DOI: 10.1016/s0022-3476(87)80500-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

1.  Metabolite amyloids: a new paradigm for inborn error of metabolism disorders.

Authors:  Ehud Gazit
Journal:  J Inherit Metab Dis       Date:  2016-06-06       Impact factor: 4.982

2.  Group work with adolescent PKU girls and their mothers.

Authors:  B E Cohen; R Weiss; R Hadar; M Normand; S Shiloh; D Elhanati
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

3.  Maternal phenylketonuria: successful outcome in four pregnancies treated prior to conception.

Authors:  B C Lynch; D B Pitt; T G Maddison; J E Wraith; D M Danks
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

Review 4.  Inherited Metabolic Disorders: Aspects of Chronic Nutrition Management.

Authors:  Suzanne W Boyer; Lisa J Barclay; Lindsay C Burrage
Journal:  Nutr Clin Pract       Date:  2015-06-16       Impact factor: 3.080

5.  Social factors and the meaning of food in adherence to medical diets: results of a maternal phenylketonuria summer camp.

Authors:  S E Waisbren; H Rokni; I Bailey; F Rohr; T Brown; J Warner-Rogers
Journal:  J Inherit Metab Dis       Date:  1997-03       Impact factor: 4.982

6.  Cognitive development in offspring of untreated and preconceptionally treated maternal phenylketonuria.

Authors:  F Güttler; H Lou; J Andresen; K Kok; I Mikkelsen; K B Nielsen; J B Nielsen
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

7.  Fetal damage due to maternal phenylketonuria: effects of dietary treatment and maternal phenylalanine concentrations around the time of conception (an interim report from the UK Phenylketonuria Register).

Authors:  I Smith; J Glossop; M Beasley
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

8.  Psychosocial factors in maternal phenylketonuria: women's adherence to medical recommendations.

Authors:  S E Waisbren; B D Hamilton; P J St James; S Shiloh; H L Levy
Journal:  Am J Public Health       Date:  1995-12       Impact factor: 9.308

Review 9.  Gestational carrier--a reproductive haven for offspring of mothers with phenylketonuria (PKU): an alternative therapy for maternal PKU.

Authors:  R O Fisch; G Tagatz; J P Stassart
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

10.  A psychosocial model of a medical problem: Maternal phenylketonuria.

Authors:  S Shiloh; S E Waisbren; H L Levy
Journal:  J Prim Prev       Date:  1989-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.